Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter F Lebowitz

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Current Problems in Cancer|November 19, 2003
Hormonal therapy of breast cancerPeter F Lebowitz, JoAnne Zujewski
Cancer Prevention Research (Philadelphia, Pa.)|May 4, 2016
Disease Interception: Myths, Mountains, and Mole HillsWilliam N Hait, Peter F Lebowitz
Nature Reviews. Drug Discovery|March 13, 2019
Moving upstream in anticancer drug developmentWilliam N Hait, Peter F Lebowitz
Journal of Translational Medicine|July 26, 2011
Deep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicineJoanna D Holbrook, Joel S Parker, Kathleen T Gallagher, et al.
Cancer|May 10, 2007
The needle in the haystack: application of breast fine-needle aspirate samples to quantitative protein microarray technologyAmy Rapkiewicz, Virginia Espina, Jo Anne Zujewski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2005
A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancerPeter F Lebowitz, Jennifer Eng-Wong, Brigitte C Widemann, et al.
Breast Cancer Research and Treatment|December 17, 2009
Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancerLarissa A Korde, Lara Lusa, Lisa McShane, et al.
European Journal of Cancer (Oxford, England : 1990)|September 18, 2012
(18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanomaMatteo S Carlino, Catherine A B Saunders, Lauren E Haydu, et al.
Journal of Clinical Pharmacology|October 8, 2009
A phase I study to characterize the safety, tolerability, and pharmacokinetics of topotecan at 4 mg/m2 administered weekly as a 30-minute intravenous infusion in patients with cancerKelly K Curtis, Jean T Hartney, Roxanne C Jewell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2004
A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancerPeter F Lebowitz, Jennifer Eng-Wong, Sandra M Swain, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Current Problems in Cancer|November 19, 2003
Hormonal therapy of breast cancerPeter F Lebowitz, JoAnne Zujewski
Cancer Prevention Research (Philadelphia, Pa.)|May 4, 2016
Disease Interception: Myths, Mountains, and Mole HillsWilliam N Hait, Peter F Lebowitz
Nature Reviews. Drug Discovery|March 13, 2019
Moving upstream in anticancer drug developmentWilliam N Hait, Peter F Lebowitz
Journal of Translational Medicine|July 26, 2011
Deep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicineJoanna D Holbrook, Joel S Parker, Kathleen T Gallagher, et al.
Cancer|May 10, 2007
The needle in the haystack: application of breast fine-needle aspirate samples to quantitative protein microarray technologyAmy Rapkiewicz, Virginia Espina, Jo Anne Zujewski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2005
A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancerPeter F Lebowitz, Jennifer Eng-Wong, Brigitte C Widemann, et al.
Breast Cancer Research and Treatment|December 17, 2009
Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancerLarissa A Korde, Lara Lusa, Lisa McShane, et al.
European Journal of Cancer (Oxford, England : 1990)|September 18, 2012
(18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanomaMatteo S Carlino, Catherine A B Saunders, Lauren E Haydu, et al.
Journal of Clinical Pharmacology|October 8, 2009
A phase I study to characterize the safety, tolerability, and pharmacokinetics of topotecan at 4 mg/m2 administered weekly as a 30-minute intravenous infusion in patients with cancerKelly K Curtis, Jean T Hartney, Roxanne C Jewell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2004
A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancerPeter F Lebowitz, Jennifer Eng-Wong, Sandra M Swain, et al.
Pageof 2